Business
Covalon Presents Evidence-Backed Innovations Making a Difference for Critically Ill Children at APHON
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced med...
About this update from Covalon Technologies Ltd.
[{"type":"text","content":"Covalon Presents Evidence-Backed Innovations Making a Difference for Critically Ill Children at APHON\n\n\n .bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }\n \n\n\n\n Covalon Technologies Ltd. (the \"Company\" or \"Covalon\") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, announced its participation in the Association of Pediatric Hematology/Oncology Nurses (APHON) 49th Annual Conference, September 25–27, 2025 in Providence, Rhode Island. The annual conference, attended by more than 800 nurse leaders from across the United States and around the world, is recognized as the premier educational experience for pediatric hematology/oncology nurses, bringing together clinicians and industry experts to advance knowledge, share research, and improve patient outcomes.\n \n\n “Pediatric hematology and oncology patients already face so many challenges as part of their treatment journey. The risk of blood stream infections and other largely preventable complications should not be one of them,” said Brent Ashton, Chief Executive Officer. “At Covalon, our mission is to deliver technologies that bring innovation and compassion together, giving clinicians tools that reduce risks, ease their daily workload, and greatly improve the care experience for children and families. We believe these solutions can help advance the standard of vascular access care.”\n \n\n At APHON this year, Covalon is building on recent milestones that showcase its momentum and leadership in vascular access innovation. Last week, the Journal of the Association for Vascular Access (JAVA) published peer-reviewed data from the Children’s Hospital at Montefiore describing how the hospital’s experience with VALGuard® Line Guard was associated with positive outcomes, including a 78% reduction in hospital-wide CLABSI rates from 2023 to 2024, and a sustained period of zero CLABSI’s (Central Line Associated Blood Stream Infections) in the Pediatric Critical Care Unit. The publication provides peer-reviewed evidence on VALGuard® and highlight its role in protecting vulnerable pediatric patients.\n \n\n In addition, new economic findings from a U.S. hospital study demonstrated that CovaClear® silicone dressing, used as a cover for primary ...